BioNTech SE
NASDAQ:BNTX

Watchlist Manager
BioNTech SE Logo
BioNTech SE
NASDAQ:BNTX
Watchlist
Price: 98.68 USD -0.39% Market Closed
Market Cap: 23.7B USD

Wall Street
Price Targets

BNTX Price Targets Summary
BioNTech SE

Wall Street analysts forecast BNTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BNTX is 138.29 USD with a low forecast of 111.1 USD and a high forecast of 179.55 USD.

Lowest
Price Target
111.1 USD
13% Upside
Average
Price Target
138.29 USD
40% Upside
Highest
Price Target
179.55 USD
82% Upside
BioNTech SE Competitors:
Price Targets
VRTX
Vertex Pharmaceuticals Inc
18% Upside
RCKT
Rocket Pharmaceuticals Inc
523% Upside
068270
Celltrion Inc
59% Upside
300653
Yantai Zhenghai Bio-Tech Co Ltd
36% Upside
ARGX
argenx SE
36% Upside
603392
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
10% Downside
MRNA
Moderna Inc
78% Upside
600161
Beijing Tiantan Biological Products Corp Ltd
67% Upside

Revenue
Forecast

Revenue Estimate
BioNTech SE

For the last 6 years the compound annual growth rate for BioNTech SE's revenue is 67%. The projected CAGR for the next 3 years is -6%.

67%
Past Growth
-6%
Estimated Growth
Estimates Accuracy
1%
Average Beat

Operating Income
Forecast

Operating Income Estimate
BioNTech SE

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-8%
Average Miss

Net Income
Forecast

Net Income Estimate
BioNTech SE

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BNTX's stock price target?
Price Target
138.29 USD

According to Wall Street analysts, the average 1-year price target for BNTX is 138.29 USD with a low forecast of 111.1 USD and a high forecast of 179.55 USD.

What is BioNTech SE's Revenue forecast?
Projected CAGR
-6%

For the last 6 years the compound annual growth rate for BioNTech SE's revenue is 67%. The projected CAGR for the next 3 years is -6%.

Back to Top